Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 37, Issue 6, 2010, Pages 1121-1128

  Kurosaka, Daitaro ^a   Hirai, Kenichiro ^a   Nishioka, Makiko ^a   Miyamoto, Yukio ^a   Yoshida, Ken ^a   Noda, Kentaro ^a   Ukichi, Taro ^a   Yanagimachi, Maimi ^a   Furuya, Kazuhiro ^a   Takahashi, Eigo ^a   Kingetsu, Isamu ^a   Fukuda, Kunihiko ^a   Yamada, Akio ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiopoietin; Clinical practice; Rheumatoid arthritis; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; C REACTIVE PROTEIN; STROMELYSIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANKLE RADIOGRAPHY; ARTICLE; BLOOD FLOW; DISEASE ACTIVITY; DOPPLER ECHOGRAPHY; ELBOW RADIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JOINT DESTRUCTION; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SHOULDER RADIOGRAPHY; WRIST RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; ULTRASONOGRAPHY, DOPPLER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77953221700     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090941     Document Type: Article

References (30)

1. Paleolog EM, Fava RA. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin Immunopathol 1998;20:73-94.
2. Walsh DA. Angiogenesis and arthritis. Rheumatology 1999;38:103-112
3. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl 2:ii60-7.
4. Taylor PC. VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res 2002;4 Suppl 3:S99-107.
5. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22. (Pubitemid 29038270)
6. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-346
7. Ballara S, Taylor PC, Reusch P, Marmé D, Feldmann M, Maini RN, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001;44:2055-2064
8. Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Ménard JF, et al. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 2007;124:158-164
9. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006;27:552-558
10. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-1466 (Pubitemid 28509902)
11. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999;274:15732-15739 (Pubitemid 129518932)
12. Mandriota SJ, Pyke C, Di Sanza C, Quinodoz P, Pittet B, Pepper MS. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. Am J Pathol 2000;156:2077-2089 (Pubitemid 30641775)
13. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005;118 part 4:771-780
14. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006;12:235-239
15. Scott BB, Zaratin PF, Colombo A, Hansbury MJ, Winkler JD, Jackson JR. Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2002;29:230-239 (Pubitemid 34118766)
16. Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A, et al. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003;62:100-107
17. Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003;30:260-268 (Pubitemid 36152587)
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
19. Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, De Groote D, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 2000;27:888-893 (Pubitemid 30389742)
20. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-581
21. Naredo E, Collado P, Cruz A, Palop MJ, Cabero F, Richi P, et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum 2007;57:116-124
22. Naredo E, Möller I, Cruz A, Carmona L, Garrido J. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:2248-2256
23. Naredo E, Rodríguez M, Campos C, Rodríguez-Heredia JM, Medina JA, Giner E, et al; Ultrasound Group of The Spanish Society of Rheumatology. Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2008;59:515-522
24. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-858
25. Kurosaka D, Hirai K, Nishioka M, Miyamoto Y, Yoshida K, Takahashi E, et al. Correlation between synovial blood flow signals and serum vascular endothelial growth factor levels in patients with refractory rheumatoid arthritis. Mod Rheumatol 2009;19:187-191
26. Strunk J, Heinemann E, Neeck G, Schmidt KL, Lange U. A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler ultrasonography and measurement of serum vascular endothelial growth factor. Rheumatology 2004;43:1480-1483
27. Walther M, Harms H, Krenn V, Radke S, Faehndrich TP, Gohlke F. Correlation of power Doppler sonography with vascularity of the synovial tissue of the knee joint in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2001;44:331-338
28. Hau M, Kneitz C, Tony HP, Keberle M, Jahns R, Jenett M. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). Ann Rheum Dis 2002;61:55-58
29. Terslev L, Torp-Pedersen S, Qvistgaard E, Kristoffersen H, Røgind H, Danneskiold-Samsøe B, et al. Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis 2003;62:178-181
30. Fiocco U, Ferro F, Vezzù M, Cozzi L, Checchetto C, Sfriso P, et al. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis 2005;64:899-905.